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Abstract
We characterized maraviroc susceptibility of dual/mixed tropic
viruses from subjects enrolled onto phase IIb study A4001029.
Maraviroc baseline plasma samples from 13 multidrug-
experienced subjects were sequenced and the HIV-1-env gene
cloned into pNL4.3Δenv to obtain recombinant viruses. The V3
region was sequenced by the Sanger method and ultradeep
sequencing. By analysing subjects having a weighted optimized
background therapy susceptibility (wOBT) score of <1, 3/7
subjects were characterized by good in vivo and in vitro response
to maraviroc therapy. Molecular docking simulations allowed us
to rationalize the maraviroc susceptibility of dual/mixed tropic
viruses. A subset of subjects with dual/mixed tropic viruses
responded to maraviroc. Further investigations are warranted of
CCR5 antagonists in subjects carrying dual/mixed tropic virus
that explore the feasible use of maraviroc in subjects that is
potentially larger than those infected with a pure R5 virus.
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Introduction
Human immunodeﬁciency virus type 1 (HIV-1) strains can be
phenotypically classiﬁed according to their ability to use CCR5
and/or CXCR4 coreceptors [1,2]. Special attention should be
paid to dual/mixed tropic viruses, which can be divided into
those more efﬁcient in using the CCR5 coreceptor (R5+/X4),
those using CXCR4 (R5/X4+) more efﬁciently and those using
both coreceptors (R5/X4) with similar efﬁciency [3–5].
Maraviroc, the only U.S. Food and Drug Administration–
approved CCR5 antagonist, demonstrated potent activity in
subjects infected by CCR5 tropic viruses [6]. Nevertheless, it
has been suggested that maraviroc could also be used to
improve therapy efﬁcacy in subjects infected with dual/mixed
tropic viruses [3,4,7,8]. The A4001029 study is a unique
exploratory, randomized, double-blind, multicenter trial
designed to assess the use of maraviroc in treatment-
experienced subjects infected with non-R5 viruses which has
proved the efﬁcacy of the regimen in 27% of subjects in the
maraviroc twice-daily arm [8].
Thus, to deeply characterize the genotypic and phenotypic
coreceptor usage of dual/mixed tropic viruses and to investigate
their in vitro susceptibility to this drug, we analysed the mar-
aviroc effect against HIV from 13 subjects enrolled onto the
A4001029 study.
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Methods
Subjects
Thirteen plasma samples randomly selected from HIV-1-
infected subjects with available baseline samples were ana-
lysed. All subjects had dual/mixed tropic viruses at screening by
standard Troﬁle assay and were treated with maraviroc ac-
cording to the study protocol [8].
Sequencing
For each baseline plasma sample, the V3 region was ampliﬁed
and sequenced by Sanger sequencing and by ultradeep
sequencing (UDPS; Roche 454-GS-FLX) [9]. The Geno2Pheno
algorithm set at <10% false-positive rate (FPR) was used to
deﬁne the non-R5 viruses.
Production of recombinant viruses
Infectious recombinant viruses were obtained by cotransfecting
2 μg of gp160 polymerase chain reaction product obtained
from each baseline plasma sample and 3 μg of pNL4.3-Δenv
plasmid.
Phenotypic tropism determination
Phenotypic tropism of recombinant viruses was evaluated by a
multiple replication cycle assay on U87MG-CD4+/CCR5+/
CXCR4+-astroglioma-expressing cells [3,7].
Phenotypic activity of maraviroc
Susceptibility to entry inhibitors (maraviroc 0.02–10 000 nM,
AMD3100 1.3–65 000 nM) was investigated in human periph-
eral blood mononuclear cells.
Structural analysis
Structural analysis was performed using the CCR5–
maraviroc–gp120 binding complex recently developed [10].
Detailed information about all methodologies are available in
the online supplementary material.
Results and discussion
Subject characteristics
Data from 13 multidrug-experienced subjects, enrolled onto
the phase IIb study A4001029, treated with maraviroc-
containing regimens, all harbouring dual/mixed tropic viruses,
were analysed. Most of them (8/13) had a wOBT score of 1.
For all subjects, recombinant viruses were successfully obtained
by cloning the entire gp160 from baseline plasma samples into a
pNL4.3Δenv plasmid (Table 1).
Genotypic characterization
V3 population sequencing was performed for all 13 pairs of
plasma samples and corresponding recombinant viruses. The
tropism prediction was concordant for 12/13 samples (92%),
with a CXCR4 tropism prediction for 11 samples (FPR < 10%).
The only discordant subject was subject 10 (plasma FPR 3.4%
vs. recombinant virus FPR 27.0%) (Table 1). By UDPS analysis,
non-R5-using species were found in all plasma samples, with a
median prevalence ranging from 3.7% to 99.6%. Interestingly, in
5/11 subjects with plasma and recombinant virus V3 population
FPR of <10%, UDPS revealed R5 species with a prevalence of
>25% (Table 1).
Phenotypic tropism characterization
By using U87MG-CD4+-CCR5+/CXCR4+-expressing cells, 12/
13 (92.3%) viruses replicated in both CXCR4+ and CCR5+ cell
lines, and thus were deﬁned as dual/mixed tropic viruses, while
one recombinant virus (ID#3) replicated only in CXCR4+ cells,
showing pure X4 tropism (Table 1). No recombinant virus
replicated solely in CCR5+ cells. According to p24 production,
three recombinant viruses were deﬁned as R5/X4 tropic for
similar p24 production in supernatants of either U87MG-
CD4+/CCR5+ or U87MGCD4+/CXCR4+ cells. Four other vi-
ruses were deﬁned as R5+/X4 for p24 production higher in
U87MG-CD4+/CCR5+ cells than in U87MG-CD4+/CXCR4+-
cells. The latter ﬁve viruses were deﬁned as R5/X4+ tropic for
p24 production higher in U87MG-CD4+/CXCR4+ cells than in
U87MG-CD4+/CCR5+ cells.
Antiviral activity of maraviroc in vitro
As expected, maraviroc was not active against the pure X4
recombinant virus (ID#3; viral replication inhibition 0% at
200 nM/10 000 nM). At a concentration of 200 nM (close to the
minimal concentration achieved in plasma of maraviroc-treated
subjects with the common dose of 300 mg) maraviroc was able
to signiﬁcantly inhibit 12 dual/mixed tropic viruses (median
(interquartile range, IQR) inhibition = 31.5% (15.5–54.5)).
According to phenotypic tropism characteristics, viral inhibition
(maraviroc 200 nM) and drug concentration causing 50% inhi-
bition (IC50) of R5
+/X4 were considerably different from those
observed for R5/X4 and R5/X4+ viruses (median (IQR) inhibi-
tion = 77% (45–86.5) vs. 16% (15–30.5) vs. 26% (19–37),
respectively; IC50 0.7 nM vs. >1000 nM vs. >1000 nM,
respectively; Supplementary Table 1). Only R5+/X4 viruses
responded to maraviroc in vitro similarly to the pure R5 virus
control (HIV BaL), reaching approximately 90% of viral inhibi-
tion at 20 nM (Fig. 1(A)). In contrast, X4 inhibitor AMD3100
(1300 nM) efﬁciently inhibited the pure X4 recombinant virus
(95% inhibition) and partially inhibited 9/12 dual/mixed tropic
viruses (median (IQR) inhibition = 43.5% (6.8–59),
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Supplementary Table 1). These results conﬁrm that dual tropic
viruses represent a swarm of different viruses with different
characteristics and different sensitivity to R5/X4 inhibitors.
Comparison between in vitro and in vivo response to
maraviroc
By comparing the in vitro and in vivo maraviroc response in a
subgroup of subjects (n = 7) with available viroimmunological
follow-up and with wOBT score of <1 (indicating a very limited
efﬁcacy of the backbone drugs), we found in 6/7 subjects a good
correlation between the two maraviroc responses. In partic-
ular, three subjects (subjects 4, 10, 12) with >25% of R5 species
in plasma at UDPS exhibited good in vivo (Fig. 1(B)) and in vitro
responses (Table 1) (median (IQR) change in viral
load = −2.1 log copies/mL (−2.05; −2.75) at 8 weeks, HIV
RNA<50 copies/mL at 24 weeks and median maraviroc IC50
4.6 nM). Conversely, 3 subjects (subjects 1, 2, 11), infected by a
viral population with >95% of X4 species were characterized by
exhibiting no or very low response in vivo and in vitro. For only
one subject (subject 13), with 98.4% of X4 species in plasma but
characterized by a R5+/X4 phenotype in vitro were the 2 mar-
aviroc responses were not concordant, with no/low response
exhibited in vivo and excellent activity exhibited in vitro.
Even if few subjects have been analysed, our results suggest
that subjects having >25% of R5 species in plasma at UDPS and
characterized by a good in vitro response to maraviroc
(IC50 < 300 nM) could potentially respond to a maraviroc-
containing regimen, even in the setting of a low wOBT score.
TABLE 1. Genotypic and phenotypic characterization
Subject ID
Phenotypic
tropism G2P FPR
UDPS
V3 mutations
MVC
IC50 (nM)
a
% Non-R5b % R5
FPR, median
(IQR)
FPR, median
(IQR)
1_RV R5/X4 1.7 R9S S11R I12I/V H13S F20W Y21R T22A G24del E25D/N/S 333
1_Plasma 1.5 99.6 0.4
1.7 (1.6–1.8) 25.2 (19.5–33.0) R9S S11R H13S F20W Y21R T22A G24del E25D/N/S
2_RV R5/X4 2.8 K10R S11G I12I/V G24D E25R I27V D29N I30I/V >10 000
2_Plasma 2.8 99.4 0.6
2.6 (1.7–2.7) 73 (27.1–96.2) K10R S11G I12I/V G24D E25R I27I/V D29N I30I/V
3_RV X4 0.2 N5S N6S N7K T8K/N/S/Q/H/R/E/D/G R9T/I K10T S11K/R
Y21H G24K E25S I27T G28E D29G I30L
>10 000
3_Plasma 0.9 88.7 11.3 N5S N6S N7K T8K/N/S/Q/H/R/E/D/G R9R/I K10T S11K/R
Y21H G24K E25S I27T G28E D29G I30L0.2 (0.1–0.7) 27.3 (13–48.9)
4_RV R5/X4+ 0.2 T2M N7Y R9K/N/S S11R I12L H13S Y21D/V/F T22A T23A
G24R E25S
266
4_Plasma 1.7 72.4 27.6 T2I/M N7Y R9K/N/S S11R I12V/L H13P/S Y21F/V T22A
T23A/T G24G/R E25E/N/D/S0.1 (0.0–0.7) 92.3 (73.3–95.8)
5_RV R5/X4+ 0.2 T8T/R R9R/K S11R H13T I14I/L A19A/V F20I/F G24K
I27D Q32K/R
>1000
5_Plasma 1.7 8.9 91.1
1.7 (0.2–6.8) 38.1 (25.5–46.0) S11S/R H13T A19A/V F20I/F Y21Y/F G24G/K
6_RV R5/X4+ 0.7 T2I K10R S11A H13G A19T F20V T22A T23A G24D E25K >1000
6_Plasma 0.7 99.5 0.5
0.7 (0.5–1.1) 18.3 (15.0–20.9) T2I K10R S11A H13G A19T F20V T22A T23A G24D E25K
7_RV R5/X4 1.1 R9S K10Q S11R H13S T22A T23S G24R E25R I27T >1000
7_Plasma 1.7 70.6 29.4
1.7 (1.1–3.8) 15.6 (15.6–21.2) R9R/S K10E/Q S11G/R H13S T22A T23S G24R E25R I27T
8_RV R5/X4+ 1.7 K10R S11R H13T I14M A19V F20Y E25D Q32K >1000
8_Plasma 1.7 77.3 22.7
1.1 (0.7–5.3) 37.7 (18.3–38.0) K10R S11R H13T I14M A19V F20Y E25D Q32K
9_RV R5/X4+ 0.1 T2E N7T S11T H13R 15–17GHIins A19S F20L E25S D29N
Q32E
>1000
9_Plasma 6.8 3.7 96.3 T2T/K/E N7N/T S11S/T I12V/I H13R/P A19A/S F20L T22T/P/A
E25E/S D29D/N Q32E1.7 (1.6–2.8) 95.8 (95.2–96.2)
10_RV R5+/X4 27 N5S S11G E25Q I27T 4.6
10_Plasma 3.4 72.2 27.8
1.8 (1.7–2.6) 27.1 (24.0–37.4) N5S T8T/I S11G G24G/E E25Q/K I27T
11_RV R5+/X4 1.7 T2E K10K/Q S11R I12I/L H13S T22A T23T/R G24G/R E25N/D
A33A/S
2600
11_Plasma 1.7 96 4 T2E K10K/Q S11R I12I/L H13S T22A T23T/R G24G/R E25N/D
A33A/S1.7 (0.8–5.8) 14.3 (13.1–16.4)
12_RV R5+/X4 17 S11G A19T F20I T22A E25Q 0.03
12_Plasma 27.9 18.7 81.3
1.7 (1.1–5.2) 27.9 (23.5–39.8) S11G A19A/T F20I T22A E25Q
13_RV R5+/X4 4.1 N5G K10R H13R R18G F20Y Y21F T22R E25D Q32K 0.7
13_Plasma 4.7 98.4 1.6 N5G K10R H13R R18R/S/G F20Y Y21F T22R G24G/A E25E/D
I30T/I R31K/R Q32Q/K4.1 (2.8–4.7) 17.2 (11.4–34.6)
_Plasma indicates virus from subject plasma; _RV, recombinant virus (pNL4.3Δenv + gp160 from subject). V3 mutations (in bold) are found associated with X4 or dual tropism [3].
Underlined mutations were found associated with MVC or VCV resistance. Consensus B was used as reference sequence. Phenotypic tropism was evaluated on U87MG-CD4+/
CXCR4+/CCR5+. Genotypic tropism was evaluated by the Geno2Pheno (G2P) algorithm using FPR at 10%.
FPR, false-positive rate; MVC, maraviroc; IC50, drug concentration causing 50% inhibition; IQR, interquartile range; PBMC, peripheral blood mononuclear cells.
aMVC IC50 was evaluated by measuring the p24 production of recombinant viruses after 7 days after infection in PBMC cultures in presence of maraviroc. IC50 for control strain BaL
was 0.2 nM; that for IIIB was >10 000 nM.
bPercentage of non-R5 species by UDPS was calculated setting G2P FPR at 10%. Similar results were obtained setting FPR at 3.75% and 5.75%, with the exception of samples 7, 8, 11
and 13.
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This ﬁnding is important from a clinical point of view. Despite
recent studies demonstrated the ability of CCR5 antagonist to
inhibit dual/mixed tropic viruses both in vivo and in vitro
[3,4,7,8], maraviroc treatment is recommended today only for
subjects having a pure R5 viral population [11]. Of note,
extending our V3 analysis at UDPS to all subjects, irrespective
of wOBT score, the cutoff of R5 species found associated with
ex vivo maraviroc response was 5% (6/8 subjects with >5% R5
species had HIV RNA<50 copies/mL at week 24 vs. 0/5 with
<5% R5 species, p 0.02). Other recent studies reported that a
prevalence of >2% of X4 species is sufﬁcient to negatively affect
the decline in viral load during maraviroc regimen [12]. In these
studies, however, it is important to mention that a cutoff FPR of
3.5% was consistently used, therefore suggesting that samples
with viral mixture with low X4% by UDPS are the ones in
which it is reasonable to expect a good in vivo response and
phenotypic susceptibility. Overall, UDPS studies with a higher
number of subjects infected with non-pure-R5 viruses are
strongly suggested; indeed, our results may support the use of
V3 UDPS, in the particular setting of subjects with few thera-
peutic options, as a rapid method to identify subjects for whom
maraviroc can be a suitable option [12,13].
Correlation between maraviroc activity and structure
analysis
Among all subjects analysed, two (subjects 2 and 11) having at
baseline very high percentage of non-R5 sequences at UDPS
(>95%) and very low FPR value by population sequencing (2.8%
and 1.7%, respectively) and phenotypically characterized by a
R5/X4 and R5+/X4 virus, respectively, responded neither in vivo
nor in vitro to maraviroc, and, interestingly, not even to
AMD3100 in vitro (Supplementary Table 1).
Both plasma and recombinant viruses of these two subjects
carried key mutations required for CXCR4 binding (e.g. S11R,
I12V, H13S, I27V, G24R, E25R) but also for CCR5 binding (e.g.
E25D, G24D) [14]. For these reasons, we raised the question
of whether the mutations observed in these nonresponsive
subjects may have an impact on interaction with the cor-
eceptors. Because of the absence of a CXCR4 crystallographic
model, we focused on the interaction network of CCR5 with
gp120, or with maraviroc in the adopted HIV-1 CCR5–
maraviroc–gp120 binding structure complex [10,15]. After
molecular dynamic simulations of CCR5–gp120 complexes in
the presence of maraviroc, the productive interactions V3 se-
quences in subjects 2 and 11 with CCR5 increased or were
superimposable to those observed for the reference YU2-WT-
V3-complex (Supplementary Table 2). Differently, in the
CCR5–maraviroc–gp120 binding complex, the productive in-
teractions of the drug remarkably decreased (465 = ID#2,
426 = ID#11S1 and 444 = ID#11S2 vs. 478 = WT), with a
consequent binding destabilizing effect. Thus, these data
conﬁrmed the phenotypic results, demonstrating the ability of
these viruses to efﬁciently bind the CCR5 coreceptor in
presence of maraviroc as well. Our results are concordant with
FIG. 1. In vitro and in vivo virological response to maraviroc. (A) Dose–response curves for maraviroc (MVC)-dependent inhibition of R5+/X4, R5/X4,
R5/X4+ and X4 human immunodeﬁciency virus type 1 (HIV-1) strains in primary peripheral blood mononuclear cells. Dots represent the percentage of
inhibition at 0.02, 0.2, 2, 20, 200, 500, 1000 and 10 000 nM MVC concentration for each virus. (B) Virological response in HIV-1-infected subjects with
weighted optimized background therapy susceptibility score of <1 receiving antiretroviral therapy including MVC 300 mg twice daily.
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other studies suggesting that maraviroc-resistant viruses may
develop an increased dependence on the CCR5/N-terminus,
most likely signaling a shift in gp120 binding to a region of
CCR5 not modiﬁed by the antagonist binding [16].
In conclusion, by using an integrated genotypic, phenotypic
and structural approach, this study provides evidence for the
existence of a wide variety of HIV-1 dual tropic viruses, with
some of them showing a substantial susceptibility against mar-
aviroc. This is clinically important since dual/mixed viruses are
frequently observed in subjects’ viral population [17–19], and
the emergence of X4/dual mixed variants correlates with a
worse clinical outcome [20]. For these reasons, this work
highlights the importance of further investigations of the activity
of CCR5 antagonists in subjects carrying dual/mixed tropic vi-
rus, exploring a feasible use of maraviroc as a therapeutic op-
tion in a subset of multidrug-failed subjects, particularly in those
with R5 species present in >25% of the viral population by
UDPS and with susceptible in vitro maraviroc phenotype.
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